FDA OK's Sunovion epilepsy drug Aptiom

The FDA has approved Sunovion's Aptiom (eslicarbazepine), an add-on therapy designed to prevent epilepsy seizures. "Some patients with epilepsy do not achieve satisfactory seizure control from existing treatments," said Dr. Eric Bastings, acting director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "It is important we continue to make new treatment options available to patients." The most common side effects include dizziness, drowsiness, nausea, headache, double-vision, vomiting, fatigue and loss of coordination. Release

Suggested Articles

Novartis is picking up Vedere Bio and its preclinical gene therapies for $150 million upfront, with the promise of another $130 million.

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.